MB
The startup develops plug-and-play RNA devices for non-invasive diagnostics and targeted therapies, enabling in situ disease detection from blood samples. Their technology facilitates early cancer diagnosis and the development of disease-specific therapeutic drugs, improving patient monitoring and surgical assistance.
Updated 3 months ago
Funding
$860K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops plug-and-play RNA devices for non-invasive diagnostics and targeted therapies, enabling in situ disease detection from blood samples. Their technology facilitates early cancer diagnosis and the development of disease-specific therapeutic drugs, improving patient monitoring and surgical assistance.